Home › Research › Topics › pet
pet
1,163 studies tagged pet, dated 1983-08-01 to 2026-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Large-scale head-to-head comparison of on- and off-target profiles of [18F]Tauvid and [18F]MK6240 tau-PET in aging and Alzheimer’s disease 2026-11-01
- Detection of tau spatial extent using MK6240 and flortaucipir PET 2026-10-28
- Soluble amyloid composition links proximal APP processing, fibrillar burden and the p-tau181 response 2026-10-22
Studies
1,163 studies carry this tag.
Date range
1983 to 2026
Top journals
- Neurology 88
- Alzheimer's & dementia : the journal of the Alzheimer's Association 58
- Brain : a journal of neurology 52
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine 52
- Alzheimer's research & therapy 34
337 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
This review article discusses the FDA's May 2025 clearance of Fujirebio's Lumipulse G blood test, the first FDA-cleared blood test for aiding Alzheimer's diagnosis (via the pTau217/beta-amyloid 1-42 ratio).
-
NODDI-derived ODI is associated with tau PET signal, even in preclinical disease and may discriminate individuals with-and without tau beyond the MTL.
-
Alzheimer disease represents a major medical and social challenge owning to the complexity of its diagnosis, especially at the preclinical stage.
-
PET imaging demonstrated high cortical brain uptake of all 3 radiotracers in Tg-ArcSwe mice.
-
35/100
Alzheimer's Disease (AD) is a significant neurological condition characterized by progressive cognitive deterioration, with prevalence rising exponentially with age.
-
In the smallest required sample of 15 cAD and 10 Aβ-negative participants, conversion error was 1.7 Centiloids at 25 Centiloids and 3.4 Centiloids at 100 Centiloids.
-
Individuals with rapid progression were more likely to have at least one APOE ε4 allele (OR: 2.08 [95% CI: 1.16–3.74], p < 0.01), higher Braak stage (2.19 [1.20–3.98], p < 0.01), higher Thal phase (2.45 [1.24–4.83], p < 0.01), more severe white matter rarefaction (1.68 [1.21–2.35], p < 0.01), and in the final 24 months of life, more frequent untreated/undertreated hyperlipidemia (1.74 [1.35–5.56], p < 0.01) and less frequent untreated/undertreated depression (0.40 [0.17–0.91], p < 0.05).
-
Machine learning enables scalable quantification of neuropathology, offering deeper phenotyping of Alzheimer's disease (AD).
-
= 0.038) over time. Physical activity was associated with less synaptic dysfunction and cognitive activity with less synaptic dysfunction and lower amyloid burden over time, albeit effect sizes were small.
-
Alzheimer’s disease (AD) is an irreversible brain condition that impairs memory and cognitive processes.
-
Participants did not differ significantly based on sex.
-
The ABC-DS cohort showed similar Aβ PET burden but had a lower prevalence of ApoE4 carriers, younger age at clinical diagnosis and autopsy, shorter PET-autopsy interval, smaller amygdala and hippocampal volumes, more advanced CERAD scores, and no atherosclerosis compared to ADRC cohort (Figure 1).
-
49/100
The proportion of false negatives from FDG-PET ranged from 11-55%.
-
Overall PiB-PET uptake increased during the first two years (before ARIA-E) and decreased during the last two years (including ARIA-E episodes) (0.03±0.05 vs. -0.04±0.04 SUVR/year, p-value=0.01, Figure 2).
-
Overall PiB-PET uptake increased during the first two years (before ARIA-E) and decreased during the last two years (including ARIA-E episodes) (0.03±0.05 vs. -0.04±0.04 SUVR/year, p-value=0.01, Figure 2).
-
AD patients exhibited a significantly higher prevalence of APOE e3/e4 and e4/e4 genotypes compared to DLB and HC (p <0.001).
-
Until recently, accurate early detection of clinical symptoms associated with Alzheimer's disease (AD) and related dementias (ADRD) has been difficult.
-
So far, we included 42 patients in our study, that were monitored for at least 7 consecutive days and nights, to form the largest database of its kind in the world.
-
The Boston v2.0 criteria have low accuracy in patients with AD dementia.
-
Here we present our research design and preliminary results in ADAD mutation carriers and controls.
-
The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task.
-
The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task.
-
47/100
Our study included 74,275 weeks of driving data (2015-2024, average follow-up 6.1 years).
-
50/100
Our study included 74,275 weeks of driving data (2015-2024, average follow-up 6.1 years).
-
While hippocampal (H) and inferior parietal lobule (IPL) atrophy are used routinely in Alzheimer's disease (AD) diagnostics, the role of enlarged choroid plexus (ChP) remains unclear.
-
Both patient groups showed significant deviations from HC, but with distinct patterns.
-
ATTRACTnet was developed in an internal test set of 799 patients (mean [SD] age, 75.1 [11.1] years; 516 [64.7%] male and 283 [35.3%] female) using 5-fold cross-validation with an additional external test set of 422 patients.
-
The Neural Network classifier achieved an accuracy of 91% with a 95% CI ranging from 0.79-0.97 and an AUC of 94%, on the test set after identifying the most significant features for AD prediction.
-
46/100
Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) refers to the aberrant accumulation of TDP-43 in the brains of ageing individuals either in isolation or in combination with neurodegenerative disease.
-
Plasma pTau217R matched CSF eMTBR-tau243 and outperformed MTBR-tau243.
-
The results showed that the best validation scores were achieved by the CNN-LSTM model after integrating clinical attributes, with an accuracy of 92.47%.
-
Our findings suggest that disease progression follows a stage-dependent MVD pattern that can identify at-risk regions.
-
Meta-analyses of epidemiological studies have suggested that Alzheimer's disease (AD) may be linked with exposure to extremely low frequency (ELF) magnetic fields (MF).
-
The four- and seven-class clustering solutions achieved high variance overlap with published microstate templates.
-
49/100
Aggregated TDP-43 is a hallmark of frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and limbic-predominant age-related TDP-43 encephalopathy (LATE), and a common co-pathology in other neurodegenerative diseases.
-
In the within-language condition, combined speech timing and lexico-semantic features yielded maximal classification (area under the receiver operating characteristic curve [AUC]=0.88), outperforming single-feature models (AUC=0.79 for timing features; AUC=0.80 for lexico-semantic features).
-
The aim of this study is to build and validate a model based on structural magnetic resonance imaging (sMRI) to predict the progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD).
-
Differential FTP-PET signal patterns showed significant negative associations with domain-specific annual rates of decline.
-
ARIA-positive patients had significantly higher Fazekas scores compared with ARIA-negative patients (1.37 versus 1.0; P = .0262), indicating a greater DWMH burden.
-
Elevated BMI/BV associated with lower BBM concentrations, especially for p-Tau217 and NfL, independent of brain amyloid burden.
-
Among 1616 participants (AD = 1498, bvFTD = 118), all algorithms achieved high accuracy (80% to 90%) and discriminatory ability (AUC = 0.89 to 0.95).
-
No adverse events occurred over the study period.
-
Juxtacortical free water fraction, determined at diffusion MRI, was higher in participants with Alzheimer disease compared with cognitively normal controls and associated with amyloid-β, tau, and neurodegeneration biomarkers, revealing two distinct spatiotemporal progression patterns with different impacts on neuroanatomic signatures and cognitive performance.
-
Alzheimer disease and its clinical variants have characteristic spatial and temporal progression patterns of amyloid and tau driving symptomatology, but the distribution of microglia density, as measured by 18kDa translocator protein (TSPO) PET, is unknown.
-
In the CU, using combined plasma Aβ42/40 and p-tau217 cut-offs for eligibility yielded the lowest sample size estimates for a comprehensive multidomain cognitive composite score, whereas sample sizes were higher for all other inclusion criteria based on single biomarkers.
-
Four progression pathways were concluded from our analyses, cognitive stability (32.8 %), sequential MCI-only decline (34.9 %), accelerated MCI-to-dementia progression (15.8 %), and rapid direct conversion (16.5 %).
-
Physical inactivity and low fitness have become global health concerns.
-
Fifty-three scans (31.74%) were rated amyloid-positive by all readers, while 62 scans (37.13%) were rated as amyloid-negative by all readers.
-
Accurate differentiation of Alzheimer's disease (AD), frontotemporal dementia (FTD), and healthy control (HC) is critical for early diagnosis and intervention of brain disorders.
From across this tag
9 of the 1,159 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Explainable machine learning for predicting longitudinal dementia status: Establishing a leakage-free benchmark
- Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations
- Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias
- Brain amyloid imaging
- Discriminative Plasma Lipidomic Signatures of Dementia with Lewy Bodies and Alzheimer’s Disease: A Targeted Mass Spectrometry and Machine Learning Approach
- Biomarker Investigation Using Multiple Brain Measures from MRI Through Explainable Artificial Intelligence in Alzheimer’s Disease Classification
- Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans
- Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
- Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease